598 related articles for article (PubMed ID: 25785968)
1. Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease.
Monteleone G; Neurath MF; Ardizzone S; Di Sabatino A; Fantini MC; Castiglione F; Scribano ML; Armuzzi A; Caprioli F; Sturniolo GC; Rogai F; Vecchi M; Atreya R; Bossa F; Onali S; Fichera M; Corazza GR; Biancone L; Savarino V; Pica R; Orlando A; Pallone F
N Engl J Med; 2015 Mar; 372(12):1104-13. PubMed ID: 25785968
[TBL] [Abstract][Full Text] [Related]
2. Impact of patient characteristics on the clinical efficacy of mongersen (GED-0301), an oral Smad7 antisense oligonucleotide, in active Crohn's disease.
Monteleone G; Di Sabatino A; Ardizzone S; Pallone F; Usiskin K; Zhan X; Rossiter G; Neurath MF
Aliment Pharmacol Ther; 2016 Mar; 43(6):717-24. PubMed ID: 26766141
[TBL] [Abstract][Full Text] [Related]
3. CCL20 Is Negatively Regulated by TGF-β1 in Intestinal Epithelial Cells and Reduced in Crohn's Disease Patients With a Successful Response to Mongersen, a Smad7 Antisense Oligonucleotide.
Marafini I; Monteleone I; Dinallo V; Di Fusco D; De Simone V; Laudisi F; Fantini MC; Di Sabatino A; Pallone F; Monteleone G
J Crohns Colitis; 2017 May; 11(5):603-609. PubMed ID: 28453765
[TBL] [Abstract][Full Text] [Related]
4. A Pharmacological Batch of Mongersen that Downregulates Smad7 is Effective as Induction Therapy in Active Crohn's Disease: A Phase II, Open-Label Study.
Marafini I; Stolfi C; Troncone E; Lolli E; Onali S; Paoluzi OA; Fantini MC; Biancone L; Calabrese E; Di Grazia A; Monteleone I; Lenti MV; Di Sabatino A; Monteleone G
BioDrugs; 2021 May; 35(3):325-336. PubMed ID: 33871807
[TBL] [Abstract][Full Text] [Related]
5. Mongersen, an Oral SMAD7 Antisense Oligonucleotide, and Crohn's Disease.
Kennedy BW
N Engl J Med; 2015 Jun; 372(25):2461. PubMed ID: 26083214
[No Abstract] [Full Text] [Related]
6. Mongersen, an Oral SMAD7 Antisense Oligonucleotide, and Crohn's Disease.
Monteleone G; Pallone F
N Engl J Med; 2015 Jun; 372(25):2461. PubMed ID: 26083213
[No Abstract] [Full Text] [Related]
7. [Good results: antisense-oligonucleotide Mongersen is in Crohn's disease].
Moskaleva M
Dtsch Med Wochenschr; 2015 May; 140(10):710-1. PubMed ID: 26171473
[No Abstract] [Full Text] [Related]
8. Smad7 and its Potential as Therapeutic Target in Inflammatory Bowel Diseases.
Laudisi F; Dinallo V; Di Fusco D; Monteleone G
Curr Drug Metab; 2016; 17(3):303-6. PubMed ID: 26651974
[TBL] [Abstract][Full Text] [Related]
9. Targeting SMAD7 in Crohn's Disease by Mongersen: Therapeutic Revolution Under Way?
Danese S; Fiorino G; Peyrin-Biroulet L
Gastroenterology; 2015 Oct; 149(4):1121-3. PubMed ID: 26319033
[No Abstract] [Full Text] [Related]
10. Smad7 Antisense Oligonucleotide-Based Therapy in Crohn's Disease: Is it Time to Re-Evaluate?
Monteleone G; Stolfi C; Marafini I; Atreya R; Neurath MF
Mol Diagn Ther; 2022 Sep; 26(5):477-481. PubMed ID: 35841457
[TBL] [Abstract][Full Text] [Related]
11. Maintenance therapy with certolizumab pegol for Crohn's disease.
Schreiber S; Khaliq-Kareemi M; Lawrance IC; Thomsen OØ; Hanauer SB; McColm J; Bloomfield R; Sandborn WJ;
N Engl J Med; 2007 Jul; 357(3):239-50. PubMed ID: 17634459
[TBL] [Abstract][Full Text] [Related]
12. Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease.
Yacyshyn BR; Barish C; Goff J; Dalke D; Gaspari M; Yu R; Tami J; Dorr FA; Sewell KL
Aliment Pharmacol Ther; 2002 Oct; 16(10):1761-70. PubMed ID: 12269969
[TBL] [Abstract][Full Text] [Related]
13. Vedolizumab as induction and maintenance therapy for Crohn's disease.
Sandborn WJ; Feagan BG; Rutgeerts P; Hanauer S; Colombel JF; Sands BE; Lukas M; Fedorak RN; Lee S; Bressler B; Fox I; Rosario M; Sankoh S; Xu J; Stephens K; Milch C; Parikh A;
N Engl J Med; 2013 Aug; 369(8):711-21. PubMed ID: 23964933
[TBL] [Abstract][Full Text] [Related]
14. A phase 1 open-label trial shows that smad7 antisense oligonucleotide (GED0301) does not increase the risk of small bowel strictures in Crohn’s disease.
Zorzi F; Calabrese E; Monteleone I; Fantini M; Onali S; Biancone L; Pallone F; Monteleone G
Aliment Pharmacol Ther; 2012 Nov; 36(9):850-7. PubMed ID: 22971085
[TBL] [Abstract][Full Text] [Related]
15. Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease.
Yacyshyn BR; Chey WY; Goff J; Salzberg B; Baerg R; Buchman AL; Tami J; Yu R; Gibiansky E; Shanahan WR;
Gut; 2002 Jul; 51(1):30-6. PubMed ID: 12077088
[TBL] [Abstract][Full Text] [Related]
16. Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial.
Vermeire S; Schreiber S; Petryka R; Kuehbacher T; Hebuterne X; Roblin X; Klopocka M; Goldis A; Wisniewska-Jarosinska M; Baranovsky A; Sike R; Stoyanova K; Tasset C; Van der Aa A; Harrison P
Lancet; 2017 Jan; 389(10066):266-275. PubMed ID: 27988142
[TBL] [Abstract][Full Text] [Related]
17. Therapy: Oral SMAD7 antisense oligonucleotide proves effective for Crohn's disease.
Ray K
Nat Rev Gastroenterol Hepatol; 2015 May; 12(5):251. PubMed ID: 25824998
[No Abstract] [Full Text] [Related]
18. Mongersen (GED-0301) for Active Crohn's Disease: Results of a Phase 3 Study.
Sands BE; Feagan BG; Sandborn WJ; Schreiber S; Peyrin-Biroulet L; Frédéric Colombel J; Rossiter G; Usiskin K; Ather S; Zhan X; D'Haens G
Am J Gastroenterol; 2020 May; 115(5):738-745. PubMed ID: 31850931
[TBL] [Abstract][Full Text] [Related]
19. Natalizumab for active Crohn's disease.
Ghosh S; Goldin E; Gordon FH; Malchow HA; Rask-Madsen J; Rutgeerts P; Vyhnálek P; Zádorová Z; Palmer T; Donoghue S;
N Engl J Med; 2003 Jan; 348(1):24-32. PubMed ID: 12510039
[TBL] [Abstract][Full Text] [Related]
20. Knockdown of Smad7 With a Specific Antisense Oligonucleotide Attenuates Colitis and Colitis-Driven Colonic Fibrosis in Mice.
Izzo R; Bevivino G; De Simone V; Sedda S; Monteleone I; Marafini I; Di Giovangiulio M; Rizzo A; Franzè E; Colantoni A; Ortenzi A; Monteleone G
Inflamm Bowel Dis; 2018 May; 24(6):1213-1224. PubMed ID: 29668937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
